PharmaVitae explores Lundbeck’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
Publisher: Datamonitor Healthcare
Published: 21 July 2020
Number of pages:49
PharmaVitae explores Lundbeck’s prescription pharmaceutical performance and outlook over 2019–29.
Overview – Lundbeck’s prescription pharmaceutical sales are forecast to grow over the forecast period.
Key themes –  Key CNS products are expected to drive continued growth  Generic market entries will erode sales of five drugs  Acquisition of Alder BioPharmaceuticals adds Vyepti to Lundbeck’s product portfolio.
Model updates (12 May 2020)
Eptinezumab name changed to Vyepti.
Model updates (6 February 2020)
Eptinezumab added to forecast after acquisition of Alder BioPharmaceuticals for $1.95bn.
Model updates (11 November 2019)
Trintellix forecast adjusted higher in the US
Cipralex forecast adjusted higher
Rexulti forecast adjusted lower in the five major EU markets due to slower than expected launch
Lu AF35700 forecast removed after company discontinued development following program review after the failure of Phase III DAYBREAK study.
Model updates (29 July 2019)
Abilify Maintena forecast adjusted higher
Rexulti forecast adjusted higher
Trintellix forecast adjusted higher
Lu AF35700 launch delayed due to Lundbeck placing the program under review.
Table of Contents
Key Drug & Company Information
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726